Pancreatic Cancer Research

ResearcherUniversity Hospital MünsterActive in the last 2 years

Sameer Abdallah Dhayat

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5314-9736; OpenAlex author ID A5002066219. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
12
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: 2 papers · 2018: 3 papers · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: none · 2023: none · 2024: 1 paper

Papers 15

  1. Correction: Flammang et al. Tumor-Suppressive miR-192-5p Has Prognostic Value in Pancreatic Ductal Adenocarcinoma. Cancers 2020, 12, 1693. Last author DOI 10.3390/cancers16162825↗
  2. Small extracellular vesicle non-coding RNAs in pancreatic cancer: molecular mechanisms and clinical implications. First author DOI 10.1186/s13045-021-01149-4↗
  3. Postoperative pancreatic fistula affects recurrence-free survival of pancreatic cancer patients. Co-author DOI 10.1371/journal.pone.0252727↗
  4. Potential of Exosomal microRNA-200b as Liquid Biopsy Marker in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers12010197↗
  5. Tumor-Suppressive miR-192-5p Has Prognostic Value in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers12061693↗
  6. Clinical impact of circulating LAPTM4B-35 in pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00432-019-02863-w↗
  7. Circulating microRNA-99 family as liquid biopsy marker in pancreatic adenocarcinoma. Last author DOI 10.1007/s00432-018-2749-7↗
  8. The ambiguous role of microRNA-205 and its clinical potential in pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00432-018-2755-9↗
  9. Clinical Impact of Epithelial-to-Mesenchymal Transition Regulating MicroRNAs in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers10090328↗
  10. Comment on: MicroRNA Expression as a Predictive Marker for Gemcitabine Response After Surgical Resection of Pancreatic Cancer. Co-author DOI 10.1245/s10434-017-6207-6↗
  11. Challenges in pancreatic adenocarcinoma surgery - National survey and current practice guidelines. Co-author DOI 10.1371/journal.pone.0173374↗
  12. SERPINB5 Promoter Hypomethylation Differentiates Pancreatic Ductal Adenocarcinoma From Pancreatitis. Last author DOI 10.1097/mpa.0000000000000526↗
  13. MicroRNA-100 and microRNA-21 as markers of survival and chemotherapy response in pancreatic ductal adenocarcinoma UICC stage II. Co-author DOI 10.1186/s13148-015-0166-1↗
  14. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1371/journal.pone.0143755↗
  15. Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer--a review. Co-author DOI 10.1002/ijc.26078↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Norbert J. Senninger · 10 shared papers, 2015–2021 · strength 0.92
  2. Moritz Reese · 4 shared papers, 2020–2024 · strength 0.83
  3. Isabelle Flammang · 4 shared papers, 2019–2024 · strength 0.68
  4. Zixuan Yang · 4 shared papers, 2019–2024 · strength 0.68
  5. Anda Ströse · 5 shared papers, 2015–2024 · strength 0.63
  6. Wolf Arif Mardin · 5 shared papers, 2011–2017 · strength 0.33
  7. Jörg Haier · 4 shared papers, 2011–2016 · strength 0.21
  8. Konrad Steinestel · 2 shared papers, 2018 · strength 0.18
  9. Max M. Träger · 2 shared papers, 2018 · strength 0.18
  10. Soeren Torge Mees · 3 shared papers, 2011–2016 · strength 0.15
  11. Qifa Ye · 1 shared paper, 2019 · strength 0.12
  12. Thorsten Vowinkel · 1 shared paper, 2017 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.